Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma.

ABSTRACT:

Background

To evaluate the efficacy and safety of everolimus, a mTOR inhibitor, on invasive malignant renal epithelioid angiomyolipoma (EAML).

Materials and methods

From Oct 2014 to May 2019, we collected data from seven patients with a definite (clinical and pathological) diagnosis of EAML received everolimus in our hospital. Targeted sequence capture array technique with next-generation of high throughput sequencing (NGS) were performed to detect mutations of TSC1/2 genes. All patients had received surgery and everolimus. The clinical efficacy and safety of the therapy were evaluated.

Results

Mutations of TSC1 and TSC2 were detected in two and three patients though targeted sequence capture array technique with NGS, respectively. Among seven patients, three had miss

SUBMITTER: Guo G 

PROVIDER: S-EPMC7870865 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature